Wanbangde Pharmaceutical Holding Group Co Ltd Total Liabilities
Wanbangde Pharmaceutical Holding Group Co Ltd total liabilities. Based on the latest financial reports, Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has total liabilities worth CN¥1.86 Billion CNY (≈ $271.72 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Wanbangde Pharmaceutical Holding Group C asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2025)
Total liabilities of Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2025. This chart illustrates how Wanbangde Pharmaceutical Holding Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Wanbangde Pharmaceutical Holding Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wanbangde Pharmaceutical Holding Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Karnov Group AB
ST:KAR
|
Sweden | Skr4.36 Billion |
|
XiAn ChenXi Aviation Technology Corp Ltd
SHE:300581
|
China | CN¥237.16 Million |
|
Capital City Bank Group
NASDAQ:CCBG
|
USA | $3.88 Billion |
|
Fluence Energy Inc
NASDAQ:FLNC
|
USA | $2.18 Billion |
|
Scholastic Corporation
NASDAQ:SCHL
|
USA | $-264.70 Million |
|
Jiangxi Huangshanghuang Group Food Co Ltd
SHE:002695
|
China | CN¥920.70 Million |
|
Hunan New Wellful Co Ltd
SHG:600975
|
China | CN¥8.74 Billion |
|
Fujian Acetron New Materials Co Ltd
SHE:300706
|
China | CN¥1.32 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Wanbangde Pharmaceutical Holding Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002082 current and non-current assets.
Liquidity & Leverage Metrics
Wanbangde Pharmaceutical Holding Group Co Ltd Total Liabilities Ratios Explained
Wanbangde Pharmaceutical Holding Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wanbangde Pharmaceutical Holding Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2025)
The table below shows the annual total liabilities of Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.78 Billion ≈ $261.01 Million |
+13.54% |
| 2024-12-31 | CN¥1.57 Billion ≈ $229.88 Million |
+2.18% |
| 2023-12-31 | CN¥1.54 Billion ≈ $224.97 Million |
+10.09% |
| 2022-12-31 | CN¥1.40 Billion ≈ $204.36 Million |
-14.15% |
| 2021-12-31 | CN¥1.63 Billion ≈ $238.04 Million |
-41.99% |
| 2020-12-31 | CN¥2.80 Billion ≈ $410.34 Million |
+48.47% |
| 2019-12-31 | CN¥1.89 Billion ≈ $276.38 Million |
+68.37% |
| 2018-12-31 | CN¥1.12 Billion ≈ $164.15 Million |
+125.90% |
| 2017-12-31 | CN¥496.58 Million ≈ $72.67 Million |
+89.65% |
| 2016-12-31 | CN¥261.85 Million ≈ $38.32 Million |
-3.12% |
| 2015-12-31 | CN¥270.28 Million ≈ $39.55 Million |
+6.12% |
| 2014-12-31 | CN¥254.69 Million ≈ $37.27 Million |
-29.46% |
| 2013-12-31 | CN¥361.07 Million ≈ $52.84 Million |
-23.03% |
| 2012-12-31 | CN¥469.09 Million ≈ $68.64 Million |
+19.60% |
| 2011-12-31 | CN¥392.22 Million ≈ $57.39 Million |
+3.09% |
| 2010-12-31 | CN¥380.46 Million ≈ $55.67 Million |
+23.77% |
| 2009-12-31 | CN¥307.39 Million ≈ $44.98 Million |
-0.67% |
| 2008-12-31 | CN¥309.46 Million ≈ $45.28 Million |
-39.62% |
| 2007-12-31 | CN¥512.51 Million ≈ $75.00 Million |
+3.78% |
| 2006-12-31 | CN¥493.85 Million ≈ $72.27 Million |
-2.95% |
| 2005-12-31 | CN¥508.84 Million ≈ $74.46 Million |
+81.42% |
| 2004-12-31 | CN¥280.48 Million ≈ $41.04 Million |
+72.03% |
| 2003-12-31 | CN¥163.05 Million ≈ $23.86 Million |
-- |
About Wanbangde Pharmaceutical Holding Group Co Ltd
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascul… Read more